Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Recombinant t-PA and platelet activity.

¹Division of Cardiology, University of Massachusetts Medical Center, Worcester.

Cleveland Clinic Journal of Medicine

|September 1, 1990

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

Journal of thrombosis and thrombolysis·2014

Same author

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Journal of clinical pharmacology·2014

Same author

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent.

Journal of thrombosis and haemostasis : JTH·2012

Same author

Antidote control of aptamer therapeutics: the road to a safer class of drug agents.

Current pharmaceutical biotechnology·2012

Same author

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.

Journal of thrombosis and thrombolysis·2011

Same author

The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).

Thrombosis and haemostasis·2011

Platelet-rich arterial clots resist clot-busting drugs like recombinant tissue-type plasminogen activator (rt-PA). Combining rt-PA with platelet blockers improves clot dissolution and prevents re-clotting.

Area of Science:

Cardiovascular Research
Hematology
Pharmacology

Background:

Platelet-rich coronary arterial occlusions show resistance to recombinant tissue-type plasminogen activator (rt-PA) mediated thrombolysis.
Erythrocyte-rich thrombi are more susceptible to lysis by rt-PA.

Purpose of the Study:

To investigate the efficacy of combined rt-PA and platelet antagonist administration in enhancing thrombolysis.
To understand the role of platelet activation in thrombus formation and post-thrombolysis reocclusion.

Main Methods:

Administration of rt-PA alone and in combination with a platelet antagonist.
Assessment of thrombolysis in platelet-rich and erythrocyte-rich occlusions.
Evaluation of reocclusion rates after thrombolysis.

Related Experiment Videos

Main Results:

Combined rt-PA and platelet antagonist therapy significantly enhanced thrombolysis compared to rt-PA alone.
The combination therapy demonstrated a reduced incidence of reocclusion.
Platelet activation appears to be a predominant factor in thrombus stability and recurrence.

Conclusions:

Combined rt-PA and platelet antagonist administration is a promising strategy for treating resistant coronary arterial occlusions.
Targeting platelet activation alongside fibrinolysis can improve outcomes in thrombolytic therapy.
Further research into the mechanisms of rt-PA and platelet interaction is warranted.